Table 3.

Effect of short daily hemodialysis on the IRLS score

IRLS ScaleBaselineMonth 4Month 12Global P
Global score
    per-protocol subcohort18 (16, 21)13 (10, 16)11 (8, 15)0.001
    ITT subcohort19 (17, 21)14 (12, 17)14 (11, 17)<0.0001
Symptoms severity subscale
    per-protocol subcohort12 (11, 14)8 (6, 11)8 (6, 10)<0.001
    ITT subcohort13 (11, 14)9 (8, 11)9 (8, 11)<0.0001
Impact on daily living subscale
    per-protocol subcohort3 (3, 4)3 (2, 4)2 (1, 3)0.05
    ITT subcohort4 (3, 5)3 (3, 4)3 (2, 4)0.003
  • The data are presented as adjusted means (95% confidence interval). Adjustment variables include use of RLS medications (at any time for per-protocol analysis and at baseline for ITT analysis), time, and interaction of these two variables. The per-protocol subcohort includes 46 participants, and the ITT subcohort includes 94 participants who had RLS at baseline. The global P values are based on testing time (baseline, month 4, and month 12) as a fixed effect from repeated measures analysis of covariance. P < 0.02 for pair-wise comparisons of baseline versus month 4 and month 12 for the IRLS global score and its two subscales (in both per-protocol and ITT subcohort), with the exception of the impact on daily living subscale comparison of baseline versus month 4.